sorafenib has been researched along with Fatty Liver, Nonalcoholic in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 7 (46.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aino, H; Hiraoka, A; Itano, S; Iwamoto, H; Kajiwara, M; Kamachi, N; Kawaguchi, T; Kawano, H; Koga, H; Matsukuma, N; Nakano, M; Niizeki, T; Noda, Y; Noguchi, K; Ogata, K; Okamura, S; Shimose, S; Shirono, T; Suga, H; Tanaka, M; Tanaka, T; Torimura, T; Yamaguchi, T; Yokokura, Y | 1 |
| Arrese, M; Debes, JD; Manica, M; Mattos, AA; Mattos, ÂZ; Pase, THS; Revelo, X; Vogel, A | 1 |
| Aldrighetti, L; Arai, T; Atsukawa, M; Burgio, V; Cabibbo, G; Casadei-Gardini, A; Cascinu, S; Cheon, J; Chon, HJ; Claudia, F; D'Alessio, A; De Cobelli, F; Di Costanzo, GG; Foschi, FG; Fukunishi, S; Hatanaka, T; Hiasa, Y; Hiraoka, A; Hirooka, M; Iavarone, M; Iijima, H; Imai, M; Ishikawa, T; Itobayashi, E; Itokawa, N; Iwamoto, H; Joko, K; Kakizaki, S; Kang, B; Kariyama, K; Kawata, K; Koizumi, Y; Kudo, M; Kumada, T; Lonardi, S; Marra, F; Masi, G; Morishita, A; Nagano, T; Naganuma, A; Nakamura, S; Niizeki, T; Nishida, N; Nishimur, T; Nouso, K; Ochi, H; Ogawa, C; Ohama, H; Okubo, T; Pedica, F; Pinato, DJ; Piscaglia, F; Pressiani, T; Ratti, F; Rimassa, L; Rimini, M; Ryoo, BY; Sakamoto, N; Scartozzi, M; Shigeo, S; Shimada, N; Sho, T; Silletta, M; Soldà, C; Suda, G; Tada, T; Tajiri, K; Takaguchi, K; Tamburini, E; Tanaka, T; Tani, J; Toyoda, H; Tsuji, K; Tsutsui, A; Ueshima, K; Yasuda, S; Yoo, C | 1 |
| Cheng, X; Fu, J; Huang, Z; Ji, YX; Jian, C; Li, H; Liao, R; Pan, S; She, ZG; Shen, LJ; Song, K; Tian, H; Tian, S; Wang, HP; Wang, X; Wang, Y; Zhang, X; Zhang, XJ; Zhu, L | 1 |
| Barbisan, LF; Cogliati, B; Da Silva, TC; de Albuquerque Landi, MF; Morais, JÁ; Oliveira, CP; Romualdo, GR; Vinken, M | 1 |
| Burns, MC; Fenton, SE; Kalyan, A | 1 |
| Azzaroli, F; Benevento, F; Cabibbo, G; Caturelli, E; Cucchetti, A; Di Marco, M; Farinati, F; Foschi, FG; Gasbarrini, A; Giannini, EG; Guarino, M; Marra, F; Masotto, A; Mega, A; Missale, G; Morisco, F; Nardone, G; Oliveri, F; Pontillo, G; Raimondo, G; Rapaccini, GL; Rodolfo, S; Svegliati-Baroni, G; Trevisani, F; Vidili, G; Zoli, M | 1 |
| Caraglia, M; Cervi, C; Di Biase, S; Lo Re, O; Panebianco, C; Pazienza, V; Porto, S; Rappa, F; Vinciguerra, M | 1 |
| Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC | 1 |
| Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H | 1 |
| Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC | 1 |
| Bellentani, S; Biasco, G; Brandi, G; De Lorenzo, S; Di Girolamo, S; Saccoccio, G | 1 |
| Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP | 1 |
| Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M | 1 |
| Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC | 1 |
3 review(s) available for sorafenib and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?
Topics: Bevacizumab; Carcinogenesis; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Sorafenib | 2022 |
Epidemiology, mutational landscape and staging of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Hepatitis B; Humans; Liver Neoplasms; Neoplasm Staging; Non-alcoholic Fatty Liver Disease; Sorafenib | 2021 |
Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Genetic Predisposition to Disease; Humans; Liver Neoplasms; Male; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
12 other study(ies) available for sorafenib and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Progression-Free Survival; Retrospective Studies; Sorafenib | 2021 |
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Propensity Score; Retrospective Studies; Sorafenib | 2022 |
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mitochondria; Non-alcoholic Fatty Liver Disease; Sorafenib | 2020 |
Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Topics: Animals; Cell Line, Tumor; Cell Survival; Coculture Techniques; Fibrosis; Hepatic Stellate Cells; Hepatocytes; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1 | 2021 |
Pattern of macrovascular invasion in hepatocellular carcinoma.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; End Stage Liver Disease; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Italy; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Male; Mesenteric Veins; Middle Aged; Neoplasm Invasiveness; Non-alcoholic Fatty Liver Disease; Patient Acuity; Portal Vein; Prognosis; Registries; Sorafenib; Survival Rate; Tumor Burden | 2021 |
Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Fasting; Gene Expression Regulation, Neoplastic; Glucose; Hep G2 Cells; Hepatic Stellate Cells; Humans; Lipopolysaccharides; Liver Cirrhosis, Experimental; Liver Neoplasms; Mice, Inbred C57BL; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Sorafenib; Time Factors | 2018 |
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirculation; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Platelet-Derived Growth Factor; Positron-Emission Tomography; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Splanchnic Circulation; Triazines; Vascular Endothelial Growth Factor A | 2014 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib | 2014 |
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden | 2016 |
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Jaundice; Liver Failure, Acute; Liver Neoplasms; Male; Muscle Weakness; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Tremor | 2015 |
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collagens; Glutathione Transferase; HSP90 Heat-Shock Proteins; Interleukin-10; Interleukin-6; Liver Cirrhosis; Matrix Metalloproteinase 9; Mitochondria, Liver; Niacinamide; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenylurea Compounds; Polarography; Protein Kinase Inhibitors; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transcription Factors | 2015 |
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; Hemodynamics; Inflammation; Liver; Male; MAP Kinase Signaling System; Necrosis; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; rho-Associated Kinases; RNA, Messenger; Sorafenib; Transplantation, Homologous | 2012 |